Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2026)
Lyell Immunopharma (LYEL) reported Interest & Investment Income of -$251000.0 for Q1 2026, down 88.72% on a YoY basis from -$2.2 million in Q1 2025, and down 712.2% sequentially from $41000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Interest & Investment Income data on file, last reported at -$251000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 88.72% year-over-year to -$251000.0; the trailing twelve-month figure through Mar 2026 stood at -$167000.0 (down 129.72% YoY), and the FY2025 full-year result was -$49000.0, down 112.73% from the prior year.
- Interest & Investment Income retreated to -$251000.0 in Q1 2026, from $41000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $3.7 million in Q1 2023 to a low of -$5.0 million in Q1 2022.
- A 5-year average of $94941.2 and a median of $7000.0 in 2024 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 253.85% in 2022, while the deepest fall reached 5251.61% in 2022.
- Tracing LYEL's Interest & Investment Income over 5 years: stood at $2.4 million in 2022, then tumbled by 54.65% to $1.1 million in 2023, then slumped by 143.15% to -$469000.0 in 2024, then soared by 108.74% to $41000.0 in 2025, then slumped by 712.2% to -$251000.0 in 2026.
- Business Quant data shows LYEL's Interest & Investment Income at -$251000.0 in Q1 2026, $41000.0 in Q4 2025, and $144000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -251,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -251,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 144,000.00 |
| Jun 30, 2025 | -101,000.00 |
| Mar 31, 2025 | -133,000.00 |
| Dec 31, 2024 | -469,000.00 |
| Sep 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | -310,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | -1.65 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -4.98 Mn |
| Dec 31, 2021 | -1.56 Mn |
| Sep 30, 2021 | -138,000.00 |
| Jun 30, 2021 | -90,000.00 |